BC
SYRE icon

Boxer Capital’s Spyre Therapeutics SYRE Stock Holding History

Boxer Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-696,480
Closed -$20.5M – 54
2024
Q3 		$20.5M Hold
696,480
– – 1.01% 27
2024
Q2 		$16.4M Buy
696,480
+446,480
+179% +$15.1M 0.86% 31
2024
Q1 		$9.48M Hold
250,000
– – 0.47% 45
2023
Q4 		$5.38M Buy
+250,000
New +$3.44M 0.27% 40
2021
Q3 		– Sell
-22,000
Closed -$3.83M – 100
2021
Q2 		$3.83M Hold
22,000
– – 0.14% 83
2021
Q1 		$4.36M Hold
22,000
– – 0.15% 74
2020
Q4 		$4.33M Hold
22,000
– – 0.14% 71
2020
Q3 		$3.9M Hold
22,000
– – 0.13% 69
2020
Q2 		$5.09M Buy
+22,000
New +$4.19M 0.22% 58

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Boxer Capital's SYRE Position: Q4 2024 in Review

Boxer Capital sold out of Spyre Therapeutics (SYRE) in Q4 2024, closing a stake of 696,480 shares — an estimated $20.5M sold.

Boxer Capital first reported a position in SYRE in Q2 2020 and held it in 9 quarters. The position peaked at $20.5M in Q3 2024. 131 funds tracked by Wall St. Rank hold SYRE as of Q4 2024.

  • Boxer Capital reported no remaining Spyre Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 696,480 Spyre Therapeutics shares in Q4 2024, an estimated $20.5M.
  • Boxer Capital first reported a position in Spyre Therapeutics in Q2 2020 and held it in 9 quarters.
  • Boxer Capital's Spyre Therapeutics position peaked at $20.5M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.